Mapping the Determinants of the CCR5 Amino-terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 Gp120-CD4 Complexes

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2001 May 18

PMID 11356961

Citations 78

Authors

E G Cormier

D N Tran

L Yukhayeva

W C Olson

T Dragic

Affiliations

Soon will be listed here.

Abstract

CD4 and CCR5 mediate fusion and entry of R5 human immunodeficiency virus type 1 (HIV-1) strains. Sulfotyrosine and other negatively charged residues in the CCR5 amino-terminal domain (Nt) are crucial for gp120 binding and viral entry. We previously showed that a soluble gp120-CD4 complex specifically binds to a peptide corresponding to CCR5 Nt residues 2 to 18, with sulfotyrosines in positions 10 and 14. This sulfopeptide also inhibits soluble gp120-CD4 binding to cell surface CCR5 as well as infection by an R5 virus. Here we show that residues 10 to 18 constitute the minimal domain of the CCR5 Nt that is able to specifically interact with soluble gp120-CD4 complexes. In addition to sulfotyrosines in positions 10 and 14, negatively charged residues in positions 11 and 18 participate in this interaction. Furthermore, the CCR5 Nt binds to a CD4-induced surface on gp120 that is composed of conserved residues in the V3 loop stem and the C4 domain. Binding of gp120 to cell surface CCR5 is further influenced by residues in the crown of the V3 loop, C1, C2, and C3. Our data suggest that gp120 docking to CCR5 is a multistep process involving several independent regions of the envelope glycoprotein and the coreceptor.

Citing Articles

Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands.

Anitha A, Narayanan P, Ajayakumar N, Sivakumar K, Kumar K J Biochem. 2022; 172(3):149-164.

PMID: 35708645 PMC: 9445593. DOI: 10.1093/jb/mvac052.

Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.

Zheng Y, Han G, Abagyan R, Wu B, Stevens R, Cherezov V Immunity. 2017; 46(6):1005-1017.e5.

PMID: 28636951 PMC: 5572563. DOI: 10.1016/j.immuni.2017.05.002.

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Sok D, Pauthner M, Briney B, Lee J, Saye-Francisco K, Hsueh J Immunity. 2016; 45(1):31-45.

PMID: 27438765 PMC: 4990068. DOI: 10.1016/j.immuni.2016.06.026.

Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry.

Cimbro R, Peterson F, Liu Q, Guzzo C, Zhang P, Miao H EBioMedicine. 2016; 10:45-54.

PMID: 27389109 PMC: 5006643. DOI: 10.1016/j.ebiom.2016.06.037.

Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.

Dogo-Isonagie C, Lee S, Lohith K, Liu H, Mandadapu S, Lusvarghi S Bioorg Med Chem. 2016; 24(8):1718-28.

PMID: 26968647 PMC: 7261409. DOI: 10.1016/j.bmc.2016.02.044.

References

Wells T, Power C, Lusti-Narasimhan M, Hoogewerf A, Cooke R, Chung C . Selectivity and antagonism of chemokine receptors. J Leukoc Biol. 1996; 59(1):53-60. DOI: 10.1002/jlb.59.1.53. View

Kwong P, Wyatt R, Robinson J, Sweet R, Sodroski J, Hendrickson W . Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998; 393(6686):648-59. PMC: 5629912. DOI: 10.1038/31405. View

Rucker J, Samson M, Doranz B, Libert F, Berson J, Yi Y . Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell. 1996; 87(3):437-46. DOI: 10.1016/s0092-8674(00)81364-1. View

Cocchi F, Devico A, Garzino-Demo A, Cara A, Gallo R, Lusso P . The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med. 1996; 2(11):1244-7. DOI: 10.1038/nm1196-1244. View

Wu L, Gerard N, Wyatt R, Choe H, Parolin C, Ruffing N . CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996; 384(6605):179-83. DOI: 10.1038/384179a0. View

Trkola A, Dragic T, Arthos J, Binley J, Olson W, Allaway G . CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996; 384(6605):184-7. DOI: 10.1038/384184a0. View

Atchison R, Gosling J, Monteclaro F, Franci C, Digilio L, Charo I . Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science. 1996; 274(5294):1924-6. DOI: 10.1126/science.274.5294.1924. View

Picard L, Simmons G, Power C, Meyer A, Weiss R, Clapham P . Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol. 1997; 71(7):5003-11. PMC: 191733. DOI: 10.1128/JVI.71.7.5003-5011.1997. View

Doranz B, Lu Z, Rucker J, Zhang T, Sharron M, Cen Y . Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol. 1997; 71(9):6305-14. PMC: 191903. DOI: 10.1128/JVI.71.9.6305-6314.1997. View

10.

Samson M, Larosa G, Libert F, Paindavoine P, Detheux M, Vassart G . The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem. 1997; 272(40):24934-41. DOI: 10.1074/jbc.272.40.24934. View

11.

Blanpain C, Doranz B, Vakili J, Rucker J, Govaerts C, Baik S . Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem. 1999; 274(49):34719-27. DOI: 10.1074/jbc.274.49.34719. View

12.

Binley J, Sanders R, CLAS B, Schuelke N, Master A, Guo Y . A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol. 2000; 74(2):627-43. PMC: 111582. DOI: 10.1128/jvi.74.2.627-643.2000. View

13.

Kwong P, Wyatt R, Sattentau Q, Sodroski J, Hendrickson W . Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol. 2000; 74(4):1961-72. PMC: 111674. DOI: 10.1128/jvi.74.4.1961-1972.2000. View

14.

Sanders R, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T . Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol. 2000; 74(11):5091-100. PMC: 110861. DOI: 10.1128/jvi.74.11.5091-5100.2000. View

15.

Dragic T, Trkola A, Thompson D, Cormier E, Kajumo F, Maxwell E . A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A. 2000; 97(10):5639-44. PMC: 25881. DOI: 10.1073/pnas.090576697. View

16.

Cormier E, Persuh M, Thompson D, Lin S, Sakmar T, Olson W . Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 2000; 97(11):5762-7. PMC: 18507. DOI: 10.1073/pnas.97.11.5762. View

17.

Menzo S, SAMPAOLESI R, Vicenzi E, Santagostino E, Liuzzi G, Chirianni A . Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors. AIDS. 1998; 12(9):985-97. View

18.

Chan S, Speck R, Power C, Gaffen S, Chesebro B, Goldsmith M . V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol. 1999; 73(3):2350-8. PMC: 104480. DOI: 10.1128/JVI.73.3.2350-2358.1999. View

19.

Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard N . Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999; 96(5):667-76. DOI: 10.1016/s0092-8674(00)80577-2. View

20.

Olson W, Rabut G, Nagashima K, Tran D, Anselma D, Monard S . Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol. 1999; 73(5):4145-55. PMC: 104194. DOI: 10.1128/JVI.73.5.4145-4155.1999. View